PAVmed can sell up to $9,400,000 of common stock through A.G.P./Alliance Global Partners under a new at-the-market agreement. Investors gain visibility into the company’s available funding capacity, a 3.0% sales commission, and the stated plan to use net proceeds for Working Capital and general corporate purposes.

Key Highlights

  • A.G.P./Alliance Global Partners will receive a 3.0% commission on aggregate gross sales.
  • PAVmed will reimburse legal fees up to $65,000 for executing the agreement.
  • PAVmed may sell up to $9,400,000 of common stock through A.G.P./Alliance Global Partners.
  • The agent’s compensation is 3.0% of aggregate gross sales proceeds.

PAVmed Inc. (NASDAQ: PAVM) may sell up to $9,400,000 of common stock through A.G.P./Alliance Global Partners under a new at-the-market agreement. The arrangement gives PAVmed access to sales made from time to time, with the shares carrying a Par Value of $0.001 per share.

$9,400,000 Stock Sales Capacity

The agreement sets the agent’s compensation at 3.0% of aggregate gross sales proceeds. PAVmed will also cover legal fees up to $65,000 at execution, up to $7,500 for each eligible quarterly representation date, and up to $12,500 for each programme refresh. The contract includes representations, warranties, covenants and indemnification provisions covering liabilities under the Securities Act. Either side may end the arrangement with written notice, while the agent can terminate immediately in certain circumstances.

Proceeds Target Working Capital

The agreement was entered into on September 9, 2026, with Dennis McGrath signing for PAVmed as president and chief financial officer. A.G.P./Alliance Global Partners is based at 590 Madison Avenue, New York, New York 10,022.